Page 127 - 《中国药房》2024年6期
P. 127

[49]  SCHWARTZBERG  L  S,MODIANO  M  R,RAPOPORT         moderate and severe vomiting caused by chemotherapy in
              B L,et al. Safety and efficacy of rolapitant for prevention   breast  cancer  patients  by  R-INVR  international  scale[J].
              of  chemotherapy-induced  nausea  and  vomiting  after         China J Mod Med,2016,26(18):136-139.
              administration of moderately emetogenic chemotherapy or   [57]  潘国华,徐媛,胡萨萨,等. 阿瑞吡坦联合昂丹司琼及地
              anthracycline and cyclophosphamide regimens in patients   塞米松防治直肠癌患者术后化疗相关性恶心呕吐临床
              with  cancer:a  randomised,active-controlled,double-  观察[J]. 药物流行病学杂志,2017,26(11):725-728.
              blind,phase 3 trial[J]. Lancet Oncol,2015,16(9):1071-  PAN G H,XU Y,HU S S,et al. Clinical observation of
              1078.                                               triple therapy with aprepitant,ondansetron and dexametha‐
          [50]  SAITO H,YOSHIZAWA H,YOSHIMORI K,et al. Effi‐      sone  on  prevention  of  adjuvant  chemotherapy  induced
              cacy and safety of single-dose fosaprepitant in the preven‐  nausea and vomiting for post-operative patients with rec‐
              tion  of  chemotherapy-induced  nausea  and  vomiting  in      tal  carcinoma[J].  Chin  J  Pharmacoepidemiol,2017,26
              patients  receiving  high-dose  cisplatin:a  multicentre,      (11):725-728.
              randomised,double-blind,placebo-controlled phase 3 trial  [58]  曹峰,侯杰,刘敏. 福沙吡坦防治术后胃癌化疗所致恶心
              [J]. Ann Oncol,2013,24(4):1067-1073.                呕 吐 的 临 床 疗 效 观 察 [J].  安 徽 医 药 ,2015,19(1):
          [51]  MATSUMOTO  K,TAKAHASHI  M,SATO  K,et  al.  A      162-163.
              double-blind,randomized,multicenter  phase  3  study  of   CAO F,HOU J,LIU M. Clinical observation of fosaprepi‐
              palonosetron  vs  granisetron  combined  with  dexametha‐  tant  in  prevention  and  treatment  of  nausea  and  vomiting
              sone  and  fosaprepitant  to  prevent  chemotherapy-induced   caused  by  chemotherapy  for  postoperative  gastric  cancer
              nausea and vomiting in patients with breast cancer recei-  [J]. Anhui Med Pharm J,2015,19(1):162-163.
              ving  anthracycline  and  cyclophosphamide[J].  Cancer   [59]  丁洁,王娟,王莉,等. 福沙匹坦预防含顺铂化疗引起恶
              Med,2020,9(10):3319-3327.                           心呕吐的疗效及安全性[J]. 现代肿瘤医学,2021,29(5):
          [52]  ZHANG Z H,YANG Y P,LU P,et al. Fosaprepitant ver‐  868-871.
              sus aprepitant in the prevention of chemotherapy-induced   DING J,WANG J,WANG L,et al. Efficacy and safety of
              nausea and vomiting in patients receiving cisplatin-based   fosaprepitant in patient with nausea and vomiting caused
              chemotherapy:a  multicenter,randomized,double-blind,  by chemotherapy[J]. J Mod Oncol,2021,29(5):868-871.
              double-simulated,positive-controlled  phase  Ⅲ  trial[J].   [60]  张桂枫,崔同建,刘振华. 阿瑞匹坦用于化疗所致恶心呕
              Ann Transl Med,2020,8(5):234.                       吐反应的临床观察[J]. 中国实用医药,2015,10(33):
          [53]  KITAYAMA H,TSUJI Y,SUGIYAMA J,et al. Efficacy     132-133.
              of  palonosetron  and  1-day  dexamethasone  in  moderately   ZHANG G F,CUI T J,LIU Z H. Clinical observation of
              emetogenic  chemotherapy  compared  with  fosaprepitant,  aprepitant in treating nausea and vomiting induced by che‐
              granisetron,and  dexamethasone:a  prospective  rando-  motherapy[J]. China Pract Med,2015,10(33):132-133.
              mized crossover study[J]. Int J Clin Oncol,2015,20(6):  [61]  陈铃 . 阿瑞匹坦联合帕诺洛司琼对于化疗后止吐效果
              1051-1056.                                          [J]. 中国妇幼健康研究,2016,27(增刊2):131-132.
          [54]  KAUSHAL P,ATRI R,SONI A,et al. Comparative evalua-  CHEN  L. Antiemetic  effect  of  aprepitant  combined  with
              tion  of  triplet  antiemetic  schedule  versus  doublet  an-  panolosetron after chemotherapy[J]. Chin J Woman Child
              tiemetic  schedule  in  chemotherapy-induced  emesis  in   Health Res,2016,27(Suppl 2):131-132.
              head and neck cancer patients[J]. Ecancermedicalscience,  [62]  WANG D S,HU M T,WANG Z Q,et al. Effect of aprepi‐
              2015,9:567.                                         tant  for  the  prevention  of  chemotherapy-induced  nausea
          [55]  HESKETH  P  J,WRIGHT  O,ROSATI  G,et  al.  Single-  and  vomiting  in  women:a  randomized  clinical  trial[J].
              dose intravenous casopitant in combination with ondanse‐  JAMA Netw Open,2021,4(4):e215250.
              tron and dexamethasone for the prevention of oxaliplatin-  [63]  董良,李海金,赵建刚,等. 帕洛诺司琼预防成人化疗所
              induced nausea and vomiting:a multicenter,randomized,  致恶心呕吐随机对照试验 Meta 分析[J]. 中华肿瘤防治
              double-blind,active-controlled,two  arm,parallel  group   杂志,2014,21(18):1461-1467.
              study[J]. Support Care Cancer,2012,20(7):1471-1478.  DONG L,LI H J,ZHAO J G,et al. Comparative efficacy
          [56]  田奕,王平,马丽君. 应用R-INVR国际量表评估阿瑞匹                      and safety of palonosetron with the first 5-HT3 receptor an‐
              坦、欧赛、地塞米松对于乳腺癌患者化疗所致中重度呕                            tagonists for the chemotherapy-induced nausea and vomi-
              吐治疗效果观察[J]. 中国现代医学杂志,2016,26(18):                   ting in Chinese patients:a meta-analysis[J]. Chin J Cancer
              136-139.                                            Prev Treat,2014,21(18):1461-1467.
              TIAN Y,WANG P,MA L J. Evaluation of the therapeutic           (收稿日期:2023-08-15  修回日期:2024-02-26)
              effect of aprepitant,oseltamipram and dexamethasone on                              (编辑:陈 宏)




          中国药房  2024年第35卷第6期                                                 China Pharmacy  2024 Vol. 35  No. 6    · 757 ·
   122   123   124   125   126   127   128   129   130   131   132